医学
肝细胞癌
肝移植
人口
统计显著性
米兰标准
内科学
移植
外科
治愈率
审查(临床试验)
辍学
预期寿命
胃肠病学
病理
经济
环境卫生
人口经济学
作者
Antonio Daniele Pinna,Feng Shen,Vincenzo Mazzaferro,Luciano De Carlis,Jian Zhou,Sasan Roayaie,Carlo Sposito,Matteo Cescon,Stefano Di Sandro,He Yi-feng,Philip J. Johnson,Alessandro Cucchetti
出处
期刊:Annals of Surgery
[Ovid Technologies (Wolters Kluwer)]
日期:2018-11-01
卷期号:268 (5): 868-875
被引量:93
标识
DOI:10.1097/sla.0000000000002889
摘要
The aim of this study was to estimate probabilities of achieving the statistical cure from hepatocellular carcinoma (HCC) with hepatic resection (HR) and liver transplantation (LT).Statistical cure occurs when the mortality of a specific population returns to values of that of general population. Resection and transplantation are considered potentially curative therapies for HCC, but their effect on the residual entire life-expectancy has never been investigated.Data from 3286 HCC patients treated with LT (n = 1218) or HR (n = 2068) were used to estimate statistical cure. Disease-free survival (DFS) was the primary survival measure to estimate cure fractions through a nonmixture model. Overall survival (OS) was a secondary measure. In both, patients were matched with general population by age, sex, year, and race/ethnicity. Cure variations after LT were also adjusted for different waiting-list drop-outs.Considering DFS, the cure fraction after LT was 74.1% and after HR was 24.1% (effect size >0.8). LT outperformed HR within all transplant criteria considered (effect size >0.8), especially for multiple tumors (>0.9) and even in presence of a drop-out up to 20% (>0.5). Considering OS, the cure fraction after LT marginally increased to 75.8%, and after that HR increased to 40.5%. The effect size of LT over HR in terms of cure decreased for oligonodular tumors (<0.5), became small for drop-out up to ∼20% (<0.2), and negligible for single tumors <5 cm (∼0.1).As other malignancies, statistical cure can occur for HCC, primarily with LT and secondarily with HR, depending on waiting-list capabilities and efficacy of tumor recurrence therapies after resection.
科研通智能强力驱动
Strongly Powered by AbleSci AI